natgillin/translations-raw huggingface dataset:
the medicine has any colour at all; there are any particles or there is a layer of foam in the vial.
je obarvano; so v njem delci ali je v viali plast pene.
The medicine improved the score of the non-responders to type A botulinum toxin as well as the score of the responders.
Zdravilo je izboljšalo rezultate tako pri bolnikih, ki se niso odzvali na botulinski toksin vrste A, kot tudi rezultate tistih, ki so se nanj odzivali.
The medicine in SANCUSO (granisetron) may not work as well and/or may affect your skin if exposed to direct sunlight or the light from sunlamps or tanning beds.
Zdravilna učinkovina v zdravilu SANCUSO (granisetron) mogoče ne bo tako dobro delovala in/ali lahko vpliva na vašo kožo, če bo izpostavljena neposredni sončni svetlobi ali svetlobi v solariju ali ležečem solariju.
The medicine in SANCUSO passes gradually through your skin into your body and, therefore, the patch is applied 1 to 2 days (24 to 48 hours) before the start of chemotherapy treatment.
Zdravilna učinkovina iz zdravila SANCUSO prehaja skozi kožo v telo postopoma, zato je treba namestiti obliž 1 do 2 dni (24 do 48 ur) pred začetkom zdravljenja s kemoterapevtiki.
The medicine in the pre-filled syringe is clear and colourless to slightly yellow.
da je zdravilo v napolnjeni injekcijski brizgi bistro in brezbarvno do rumenkasto.
The medicine is a clear to almost clear, colourless nasal spray, solution.
Zdravilo je bistra do skoraj bistra, brezbarvna raztopina za pršilo za nos.
The medicine is a dark brown liquid.
Zdravilo je v obliki temno rjave tekočine.
The medicine is a solution which is given by injection into a muscle or, if more suitable, into a vein.
Zdravilo je raztopina, ki se daje z injiciranjem v mišico ali v veno, če je slednje primernejše.
The medicine is a white nasal spray suspension contained in an amber glass bottle, fitted with a pump.
Pršilo za nos je bela suspenzija v rumenorjavi steklenički, zaprti s pršilnikom.
the medicine is any color besides colorless to yellowish any part of the syringe appears to be damaged
je zdravilo drugačne barve od brezbarvne do rumenkaste, je kateri koli del napolnjene injekcijske brizge videti poškodovan.
the medicine is any colour besides colourless to light yellow
je zdravilo kakršne koli druge barve razen brezbarvno do rahlo rumeno;
The medicine is available as 10 mg tablets and taken at a dose of one tablet every day.
Zdravilo je na voljo v obliki 10-mg tablet, odmerek, ki ga je treba zaužiti, pa je ena tableta na dan.
The medicine is available as a concentrate (4mg/5ml) which is made up into a solution for infusion (drip) into a vein.
Na voljo je v obliki koncentrata (4 mg/5 ml) za pripravo raztopine za infundiranje (kapalne infuzije v veno).
The medicine is available as a solution for injection in vials of different strengths and volumes.
Zdravilo je na voljo v obliki raztopine za injiciranje v vialah z različnimi jakostmi in prostorninami.
The medicine is available as tablets (50 mg) and the recommended dose is two tablets twice a day taken together with food.
Zdravilo je na voljo v obliki tablet (50 mg), priporočeni odmerek pa je dve tableti dvakrat na dan, ki se vzameta skupaj s hrano.
the medicine is cloudy
je zdravilo motno,
the medicine is cloudy
je zdravilo motno;
the medicine is cloudy or hazy;
je motno ali megleno;
The medicine is cloudy or there are particles in it.
je zdravilo motno ali so v njem delci.
The medicine is cloudy, is distinctly brown, or has small particles.
Zdravilo je motno, izrazito rjave barve ali pa vsebuje majhne delce.
The medicine is contained inside very small droplets of fat called “liposomes”.
Zdravilna učinkovina se nahaja v zelo majhnih kapljicah maščobe, ki se imenujejo liposomi.
The medicine is given by injection into a vein about 90 minutes before obtaining an image from a PET scan.
Zdravilo se daje z injiciranjem v veno približno 90 minut pred slikanjem s PET.
The medicine is given in two equally divided doses - once in the morning and once in the evening at about the same time each day.
Zdravilo vzemite razdeljeno na dva enaka odmerka, enkrat zjutraj in enkrat zvečer, vsak dan ob približno istem času.
The medicine is given into a vein by slow injection usually lasting around one minute.
Zdravilo se daje v veno s počasnim injiciranjem, ki običajno traja približno eno minuto.
The medicine is injected under your skin and can be given by yourself or someone else (caregiver).
Zdravilo se injicira pod kožo; injicirate si ga lahko sami, ali vam ga injicira kdo drug (negovalec).
The medicine is made up immediately before being injected under the skin.
Zdravilo se pripravi neposredno pred injiciranjem pod kožo.
The medicine is not authorised for use in horses producing milk for human consumption.
Zdravilo ni odobreno za uporabo pri konjih v laktaciji, katerih mleko je namenjeno prehrani ljudi.
The medicine is not recommended in patients with severely reduced kidneys or liver function.
Zdravilo ni priporočeno pri bolnikih z močno zmanjšanim delovanjem ledvic ali jeter.
The medicine is stable in the pump for 45 days at 37°C.
V črpalki je zdravilo stabilno 45 dni pri temperaturi 37 °C.
The medicine is to be given during or straight after a feed.
Zdravilo je treba dati med obrokom ali takoj po njem.
The medicine is used in patients who have a normal heart rhythm but whose heart rate is at least 70 beats per minute.
Zdravilo se uporablja pri bolnikih z normalnim srčnim ritmom, ki pa ne sme biti manjši od 70 utripov na minuto.
The medicine is used in two different situations:
Zdravilo se uporablja v dveh različnih primerih:
The medicine is used to help in the diagnosis of the following conditions in adults (aged 18 years or over): movement disorders such as those seen in Parkinson’s disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles.
Zdravilo se uporablja za pomoč pri diagnosticiranju naslednjih bolezenskih stanj pri odraslih (starejših od 18 let): težav pri gibanju, kakršne se opazijo pri Parkinsonovi bolezni in drugih sorodnih boleznih, kjer izguba živčnih celic privede do tremorja (tresenja), motenj pri hoji in otrplosti mišic.
The medicine is used together with another hormone called Follicle Stimulating Hormone, (FSH), to bring about the development of follicles, which are in the ovary, the structures maturing the eggs (ova).
Zdravilo se uporablja v kombinaciji z drugim hormonom, ki se imenuje folikle stimulirajoči hormon, FSH, za spodbujanje razvoja foliklov, ki se nahajajo v jajčniku, v strukturi, v katerih zorijo jajčeca (ova).
The medicine may be taken with or without food.
Zdravilo lahko jemljete s hrano ali brez.
The medicine may not be tasted or felt, even when using the inhaler correctly.
Zdravila morda ne boste ne okusili ne občutili, tudi če inhalator uporabljate pravilno.
The medicine must also not be used in patients with conditions putting them at risk of major bleeding, such as an ulcer in the gut, or in patients being treated with other anticoagulant medicines except in specific circumstances (see summary of product characteristics).
Zdravilo se prav tako ne sme uporabljati pri bolnikih z obolenji, pri katerih obstaja tveganje za večjo krvavitev, kot so razjede v črevesju, ali pri bolnikih, ki prejemalo druga zdravila proti strjevanju krvi razen v posebnih okoliščinah (glejte povzetek glavnih značilnosti zdravila).
The medicine must be given using a type of nebuliser known as a ‘dosimetric’ nebuliser, which stops automatically when the correct dose has been delivered.
Zdravilo se mora jemati s pomočjo posebnega nebulatorja s sistemom za odmerjanje (dozimetričnega nebulatorja), ki se samodejno ustavi takrat, ko je bil odmerjen ustrezni odmerek.
The medicine must be infused slowly at first.
Zdravilo je treba najprej infundirati počasi.
The medicine must be injected ‘intrathecally’ (directly into the spinal fluid in the space that surrounds the spinal cord and the brain).
Zdravilo mora biti injicirano „intratekalno“ (neposredno v spinalno tekočino v prostor, ki obkroža hrbtenjačo in možgane).
The medicine must not be frozen.
Zdravilo ne sme zmrzniti.
The medicine must not be used in patients who have or are suspected to have an infection of the eye or the tissues around the eye.
Zdravilo se ne sme uporabljati pri bolnikih, ki imajo ali ki bi lahko imeli okužbo očesa ali tkiv okoli očesa.
The medicine packs containing Imnovid capsules will carry a warning on the risk of severe birth defects.
Na škatlicah, ki vsebujejo kapsule zdravila Imnovid, bo opozorilo o tveganju za hude okvare ploda.
The medicine should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Zdravilo mora biti bistro do rahlo opalescentno, brezbarvno ali bledorumeno ter lahko vsebuje majhne bele ali skoraj prosojne delce beljakovine.
The medicine should be injected when the first sign of bleeding occurs
Zdravilo je treba injicirati, ko se pojavi prvi znak krvavitve.
The medicine should be injected within 5 minutes after the cap has been removed.
Zdravilo si injicirajte v roku 5 minut po odstranitvi pokrovčka.
The medicine should be introduced into the tube leaving the body (arterial line) at the start of the dialysis session.
Zdravilo je treba vbrizgati v cevko, ki vodi kri iz telesa (arterijska linija), na začetku dialize.
The medicine should not be used for more than 28 days after it has been mixed.
Zdravila se ne sme uporabljati več kot 28 dni potem, ko je bilo zmešano.
The medicine should not normally be used in dogs suffering from Cushing’s syndrome (a disorder where the body produces too much natural steroid), and in young animals (under 7 months of age) as steroids are known to slow growth.
Zdravilo se običajno ne uporablja pri psih s Cushingovim sindromom (motnja, pri kateri telo proizvede preveč naravnega steroida) in pri mladih živalih (ki še nimajo 7 mesecev), saj je znano, da steroidi upočasnjujejo rast.
The medicine should only be given by a healthcare professional.
Zdravilo smejo dajati samo zdravstveni delavci.
The medicine was also compared with placebo in another main study in 445 patients with PAH.
Zdravilo so s placebom primerjali še v eni glavni študiji, v katero so vključili 445 bolnikov s PAH.
The medicine was compared with placebo (a dummy treatment) in 360 patients, atenolol (a beta-blocker) in 939 patients and amlodipine (another medicine used to treat angina) in 1,195 patients.
Zdravilo so primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 360 bolnikih, atenololom (antagonistom adrenergičnih receptorjev beta) pri 939 bolnikih in amlodipinom (drugim zdravilom za zdravljenje angine pektoris) pri 1 195 bolnikih.
The medicine was compared with placebo (a dummy treatment) in 360 patients, atenolol (a beta-blocker) in 939 patients and amlodipine (another medicine used to treat angina) in 1,195 patients.
Zdravilo so primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 360 bolnikih, atenololom (zaviralcem receptorjev beta) pri 939 bolnikih in amlodipinom (drugim zdravilom za zdravljenje angine pektoris) pri 1 195 bolnikih.
The medicine was effective in patients with all three types of homocystinuria.
Zdravilo je bilo učinkovito pri bolnikih z vsemi tremi tipi homocistinurije.
The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Noxafil group, and 8% in the comparator groups.
Pri bolnikih z rakom je bilo zdravilo Noxafil učinkovitejše od flukonazola ali itrakonazola – v skupini, ki je prejemala zdravilo Noxafil, se je okužba razvila pri 2 % bolnikov, v primerjalni skupini pa pri 8 %.
The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Posaconazole SP group, and 8% in the comparator group.
Pri rakavih bolnikih je bilo zdravilo Posaconazole SP učinkovitejše kot flukonazol ali itrakonazol – v skupini, ki je prejemala zdravilo Posaconazole SP, sta okužbo razvila 2 % bolnikov, v primerjalni skupini pa 8 %.
The Medicines Company UK Ltd 115L Milton Park, Abingdon Oxfordshire OX14 4SA UNITED KINGDOM
The Medicines Company UK Ltd 115L Milton Park, Abingdon Oxfordshire OX14 4SA VELIKA BRITANIJA
The Medicines Company UK Ltd Puh./tel. +358 (0) 800774218 tai +358 (0) 972519943
The Medicines Company UK Ltd Tfn : +46 (0) 20100527 eller +46 (0) 859366368
The Medicines Company UK Ltd Tel : +31 (0) 8003712001 of +31 (0) 707709201
The Medicines Company UK Ltd Tlf.: +47 80056935 eller +47 22310956
The Medicines Company UK Ltd Tel : +356 80062399 jew +356 27780987
The Medicines Company UK Ltd Tel : +31 (0) 8003712001 of +31 (0) 707709201
The Medicines Company UK Ltd Tel : +386 (0) 80080631 ali +386 (0) 18888602
The Medicines Company UK Ltd Tel : +421 (0) 268622610 alebo +421 (0) 268622610
The Medicines Company UK Ltd Tel : +421 (0 )268622610 alebo +421 (0) 268622610
The Medicines Company UK Ltd Puh./tel. +358 (0) 800774218 tai +358 (0) 972519943
The Medicines Company UK Ltd Tel : +43 (0) 800070265 oder +43 (0) 1206092417
The Medicines Company UK Ltd Tel.: +48 800702695 lub +48 223060790
The Medicines Company UK Ltd Tel : +44 (0)800 587 4149 or +44 (0)203 684 6344
The Medicines Company UK Ltd Tel.
The Medicines Company UK Ltd Tel. : +36 (0) 680986235 vagy +36 (0) 617777410
The Medicines Company UK Ltd Tel : +356 80062399 jew +356 27780987
The Medicines Company UK Ltd Tel: 00800 843 633 26 sau +41 44 828 1084
The Medicines Company UK Ltd Tel : +386 (0) 80080631 ali +386 (0) 18888602
The Medicines Company UK Ltd Tlf.: +47 80056935 eller +47 22310956
The Medicines Company UK Ltd Tel : +43 (0) 800070265 oder +43 (0) 1206092417
The medicines in Akynzeo attach to the receptors in the nervous system through which serotonin and substance P work: netupitant (an NK1 receptor antagonist) blocks the receptors for substance P, and palonosetron (a 5- HT3 receptor antagonist) blocks certain receptors for serotonin.
Zdravili, ki ju vsebuje zdravilo Akynzeo, se pritrdita na receptorje v živčevju, prek katerih delujeta serotonin in snov P: netupitant (ki je antagonist receptorjev NK1) zavira receptorje za snov P, palonosetron (ki je antagonist receptorjev 5-HT3) pa zavira določene receptorje za serotonin.
The medicines in the following list must not be taken during your course of VFEND treatment:
Med zdravljenjem z zdravilom VFEND ne smete jemati zdravil, ki so na spodnjem seznamu:
The medicines in the following list must not be taken during your Voriconazole Hospira treatment:
Med zdravljenjem z zdravilom Vorikonazol Hospira ne smete jemati zdravil, ki so na spodnjem seznamu:
The medicines used for this treatment can damage the lining of the blood vessels in the liver, leading to the formation of clots and obstruction of the vessels seen in VOD.
Zdravila, ki se uporabljajo za to zdravljenje, lahko poškodujejo notranjo plast krvnih žil v jetrih, kar povzroči nastanek strdkov in zaporo žil, značilno za venookluzivno bolezen jeter.
The medicines used in combincation with Lumark could affect your ability to drive and to use machines.
Zdravila, uporabljena v kombinaciji z radionuklidnim predhodnikom Lumark, lahko vplivajo na vašo sposobnost upravljanja vozil in strojev.
The medicines were used as an add- on to ciclosporin and corticosteroids.
Zdravila so uporabljali kot dodatek kombinaciji ciklosporina in kortikosteroidov.
The medicine’s effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during the treatment period.
Učinkovitost zdravila so merili s spremljanjem števila bolnikov, pri katerih je prišlo do težav zaradi strdkov v žilah ali ki so med zdravljenjem umrli zaradi katerega koli razloga.
The medicine’s effects were maintained for up to a year in two of the studies.
V dveh študijah so se učinki zdravila ohranili do enega leta.
The medicine’s effects were maintained for up to a year in two of the studies.
V dveh študijah so učinkovanje zdravila vzdrževali do enega leta.
The melphalan recommended starting dose is 0.1 to 0.2 mg/kg daily according to bone marrow reserve along with a further 50% dose reduction for moderate (creatinine clearance: ≥ 30 but < 50 mL/minute) or severe (CrCl: < 30 mL/minute) renal insufficiency.
Priporočeni začetni odmerek melfalana je 0,1 do 0,2 mg/kg na dan glede na rezervo kostnega mozga, odmerek se zmanjša še za nadaljnjih 50 % pri zmerni (očistek kreatinina: ≥ 30, vendar < 50 ml/minuto) ali hudi (CrCl: < 30 ml/minuto) insuficienci ledvic.
The melted tablet may be swallowed with or without water.
Raztopljeno tableto lahko pogoltnete z nekaj vode ali brez nje.
The Memantine ratiopharm treatment initiation pack is only to be used for the beginning of the treatment with Memantine ratiopharm.
Pakiranje za uvajalno zdravljenje Memantin ratiopharm se uporablja samo na začetku zdravljenja z zdravilom Memantin ratiopharm.
The membrane is resorbed over the months following implantation.
Membrana se v nekaj mesecih po vsaditvi resorbira.
The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosysthesis pathway.
Pot presnovne aktivacije vključuje sekvenčno hidrolizo karboksil-esternega dela, ki jo katalizira humani katepsin A (CatA) ali karboksilesteraza 1 (CES1) in cepitev fosforamidata z nukleotid-vezajočo beljakovino s histidinsko triado 1 (HINT1, histidine triad nucleotide-binding protein 1), čemur sledi fosforilacija po biosintezni poti pirimidinskih nukleotidov.
The metabolic disposition of bazedoxifene in postmenopausal women has been determined following oral administration of 20 mg of radiolabeled bazedoxifene.
Presnovo bazedoksifena so ugotavljali pri ženskah v postmenopavzi po peroralni uporabi 20- miligramskega odmerka radioaktivno označenega bazedoksifena.
The metabolic disposition of CE and bazedoxifene, after administration of CE/bazedoxifene, has not been studied.
Presnove CE in bazedoksifena po uporabi kombinacije CE/bazedoksifen niso raziskovali.
The metabolisation of pitolisant in humans is not completely characterized.
Značilnosti presnove pitolizanta pri človeku niso popolnoma znane.
The metabolism is qualitatively similar in rats, humans, cattle and pigs (including mini-pigs), although quantitatively there are differences.
Presnavljanje je kakovostno podobno pri podganah, ljudeh, govedu in prašičih (tudi pri mini prašičih), , količinsko pa se razlikuje.
The metabolism is qualitatively similar in rats, humans, cattle and pigs (including mini-pigs), although quantitatively there are differences.
Presnavljanje je kakovostno pri podganah, mini prašičih, ljudeh, govedih in prašičih podobno, količinsko pa se razlikuje.
The metabolism of arsenic trioxide involves oxidation of arsenious acid (AsIII), the active species of arsenic trioxide, to arsenic acid (AsV), as well as oxidative methylation to monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases, primarily in the liver.
Presnova arzenovega trioksida poteka z oksidacijo arzenaste kisline (AsIII), aktivne komponente arzenovega trioksida, v arzenovo kislino (AsV), ter z oksidativno metilacijo v monometilarzonično kislino (MMAV) in dimetilarzinično kislino (DMAV) z metiltransferazami, pretežno v jetrih.
The metabolism of asparaginase is not known but thought to occur via degradation within the reticulo- histiocytic system and by serum proteases.
Presnova asparaginaze ni znana, mislijo pa, da poteka preko degradacije v retikulo-histiocitnem sistemu in s posredovanjem serumskih proteaz.
The metabolism of dabrafenib is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy- dabrafenib, which is further oxidised via CYP3A4 to form carboxy-dabrafenib.
Presnova dabrafeniba poteka predvsem preko CYP2C8 in CYP3A4; nastane hidroksidabrafenib, ki se s CYP3A4 naprej oksidira, s čimer nastane karboksidabrafenib.
The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyltransferase 1A9 (UGT1A9).
Presnova dapagliflozina poteka predvsem z glukuronidno konjugacijo preko UDP-glukuronoziltransferaze 1A9 (UGT1A9).
The metabolism of esomeprazole is not significantly changed in elderly patients (71-80 years of age).
Pri starejših osebah (71-80 let) presnova esomeprazola ni bistveno spremenjena.
The metabolism of intravenous lidocaine is inhibited by co-administration of propranolol, resulting in a 25% increase in lidocaine concentrations.
Presnovo intravenoznega lidokaina zavira sočasna uporaba propranolola, posledica pa je 25- odstotno povečanje koncentracije lidokaina.
The metabolism of Perjeta has not been directly studied.
Presnove zdravila Perjeta niso neposredno proučevali.
The metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and interactions are not expected with ritonavir.
Presnova pravastatina in fluvastatina ni odvisna od CYP3A in medsebojnega delovanja z ritonavirjem ni pričakovati.
The metabolism of pravastatin, and fluvastatin is not dependent on CYP3A4, and interactions are not expected withnelfinavir.
Presnova pravastatina in fluvastatina ni odvisna od CYP3A4, zato ni pričakovati medsebojnega delovanja z nelfinavirjem.
The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two- three fold increased blood concentration and greater degrees of clinical beta-blockade.
Presnovo propranolola zmanjšuje sočasna uporaba kinidina, ki povzroči od dva- do trikratno povečanje koncentracije v krvi in višje stopnje kliničnih beta blokad.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-Aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
Presnova razagilina poteka preko dveh glavnih poti: N-dealkilacije in/ali hidroksilacije do presnovkov: 1-aminoindana, 3- hidroksi-N-propargil-1 aminoindana in 3-hidroksi-1-aminoindana.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-Aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
Presnova razagilina poteka preko dveh glavnih poti: N-dealkilacije in/ali hidroksilacije do presnovkov: 1-aminoindana, 3-hidroksi-N- propargil-1 aminoindana in 3-hidroksi-1-aminoindana.
The metabolism of the medicinal product is slowed in patients with mild to moderate liver insufficiency (Child-Pugh Class A and B), which leads to an increased plasma concentration of entacapone in both the absorption and elimination phases (see section 4.3).
Pri bolnikih z blago do zmerno insuficienco jeter (skupini A in B po Child–Pughovi lestvici), je presnova zdravila upočasnjena, kar povzroči zvišanje koncentracije entakapona v plazmi tako v fazi absorpcije kot v fazi odstranjevanja iz telesa (glejte poglavje 4.3).
The metabolism of valdecoxib may increase when co-administered with enzyme inducers such as rifampicin, phenytoin, carbamazepine or dexamethasone.
Presnova valdekoksiba se lahko poveča ob sočasni uporabi induktorjev encimov, kakršni so rifampicin, fenitoin, karbamazepin in deksametazon.
The metabolites and parent are eliminated from the body via urinary and biliary excretion with the majority eliminated in the bile.
Metaboliti in izhodiščna snov se izločilo iz telesa preko ledvic in jeter, večinoma preko žolča.
The metabolites are eliminated from plasma and urine in 2 phases, for which half-lives of about 2 and 5 hours (plasma) and 2 and 18 hours (urine) have been calculated.
Presnovki se iz plazme in seča izločajo v dveh fazah, za kateri sta izračunana razpolovna časa približno 2 in 5 ur (plazma) ter 2 in 18 ur (seč).
The metabolites are excreted in the urine.
Presnovki se izločajo s sečem.
The metabolites hydroxy-dalbavancin and mannosyl aglycone have been detected in urine (< 25 % of administered dose).
V urinu so zaznali presnovka hidroksi- dalbavancin in manosil aglikon (< 25 % predpisanega odmerka).
The Metalyse solvent is water for injections.
Vehikel zdravila Metalyse je voda za injekcije.